Please use this identifier to cite or link to this item:
Title: Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa
Author: Guerra Mendoza, Yolanda
Garric, Elodie
Leach, Amanda
Lievens, Marc
Ofori-Anyinam, Opokua
Pirçon, Jean-Yves
Stegmann, Jens-Ulrich
Vandoolaeghe, Pascale
Otieno, Lucas
Otieno, Walter
Owusu-Agyei, Seth
Sacarlal, Jahit
Masoud, Nahya Salim
Sorgho, Hermann
Tanner, Marcel
Tinto, Halidou
Valea, Innocent
Mtoro, Ali Takadir
Njuguna, Patricia
Oneko, Martina
Otieno, Godfrey Allan
Otieno, Kephas
Gesase, Samwel
Hamel, Mary J.
Hoffman, Irving
Kaali, Seyram
Kamthunzi, Portia
Kremsner, Peter G.
Lanaspa, Miguel
Lell, Bertrand
Lusingu, John
Malabeja, Anangisye
Aide, Pedro Carlos Paulino
Akoo, Pauline
Ansong, Daniel
Asante, Kwaku Poku
Berkley, James A.
Adjei, Samuel
Agbenyega, Tsiri
Agnandji, Selidji Todagbe
Schuerman, Lode
Keywords: Vacuna de la malària
Àfrica subsahariana
Malaria vaccine
Sub-Saharan Africa
Issue Date: 23-Apr-2019
Publisher: Taylor & Francis
Abstract: A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed RTS,S/AS01 vaccine efficacy against malaria. We now present in-depth safety results from this study. 8922 children (enrolled at 5-17\xC2\xA0months) and 6537 infants (enrolled at 6-12\xC2\xA0weeks) were 1:1:1-randomized to receive 4 doses of RTS,S/AS01 (R3R) or non-malaria control vaccine (C3C), or 3 RTS,S/AS01 doses plus control (R3C). Aggregate safety data were reviewed by a multi-functional team. Severe malaria with Blantyre Coma Score \xE2\x89\xA42 (cerebral malaria [CM]) and gender-specific mortality were assessed post-hoc. Serious adverse event (SAE) and fatal SAE incidences throughout the study were 24.2%-28.4% and 1.5%-2.5%, respectively across groups; 0.0%-0.3% of participants reported vaccination-related SAEs. The incidence of febrile convulsions in children was higher during the first 2-3 days post-vaccination with RTS,S/AS01 than with control vaccine, consistent with the time window of post-vaccination febrile reactions in this study (mostly the day after vaccination). A statistically significant numerical imbalance was observed for meningitis cases in children (R3R: 11, R3C: 10, C3C: 1) but not in infants. CM cases were more frequent in RTS,S/AS01-vaccinated children (R3R: 19, R3C: 24, C3C: 10) but not in infants. All-cause mortality was higher in RTS,S/AS01-vaccinated versus control girls (2.4% vs 1.3%, all ages) in our setting with low overall mortality. The observed meningitis and CM signals are considered likely chance findings, that - given their severity - warrant further evaluation in phase IV studies and WHO-led pilot implementation programs to establish the RTS,S/AS01 benefit-risk profile in real-life settings.
Note: Reproducció del document publicat a:
It is part of: Human Vaccines & Immunotherapeutics, 2019
Related resource:
ISSN: 2164-5515
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
GuerraMendozaY_Hum_Vaccin_Immunother_2019.pdf2.91 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons